Temoporfin

替莫泊芬

Report date: 2022/12/04 16:30:43
NME

Base Information

Drug NameTemoporfin
Drug Alias NameFoscanFosgelEF-9m-THPCKW-2345
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionReactive oxygen species stimulantsPhotosensitizers
TargetsReactive oxygen species
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and Neck +[6] 
Global Approved IndicationsSquamous Cell Carcinoma of Head and Neck
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2001/10/24
Country/TerritoryUnited StatesEUHong Kong
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBiolitec
China Registration ClassN/A

Develop Information

Active CompaniesChinese University Of Hong Kong (Cuhk)Biolitec Pharma Ltd
Inactive CompaniesRoswell Park Cancer InstituteQuintiles, IncUniversity of Arkansas
Active IndicationsSquamous Cell Carcinoma of Head and NeckKlatskin TumorCholangiocarcinoma
Inactive IndicationsCarcinoma, Non-Small-Cell LungHead and Neck NeoplasmsNeoplasms

Other Information

ATC CodeL01XD05
Related LinksWikipediaKEGG